Sandoz Archives -

Novartis’ generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which

Sandoz, Ares extend digital alliance on antimicrobial resistance

https://pharmaphorum.com/news/sandoz-ares-extend-digital-alliance-on-antimicrobial-resistance/

News/ News/ Sales and Marketing

Sandoz bulks up ahead of possible sale with Coalesce buy

Phil Taylor generics, M&A, Novartis, respiratory, Sandoz 0 Comment

Novartis may be planning to sell off its generics business Sandoz, but that hasn’t stopped it investing in

Sandoz bulks up ahead of possible sale with Coalesce buy

https://pharmaphorum.com/news/sandoz-bulks-up-ahead-of-possible-sale-with-coalesce/

News/ News/ Sales and Marketing

No news anytime soon on Sandoz sale, says Novartis

Phil Taylor Financial, generics, M&A, Novartis, Sandoz 0 Comment

Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics

No news anytime soon on Sandoz sale, says Novartis

https://pharmaphorum.com/news/no-news-anytime-soon-on-sandoz-sale-says-novartis/

News/ News/ Sales and Marketing

Novartis may have found a buyer for Sandoz; report

Phil Taylor generic, M&A, Novartis, Sandoz, switzerland 0 Comment

Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there

Novartis may have found a buyer for Sandoz; report

https://pharmaphorum.com/news/novartis-may-have-found-a-buyer-for-sandoz-report/

News/ News/ Sales and Marketing

Swiss socialists say government should buy Sandoz

Phil Taylor M&A, Novartis, Sandoz, switzerland 0 Comment

Switzerland’s Social Democratic Party has argued that the government should step in and acquire Novartis’ generics unit Sandoz

Swiss socialists say government should buy Sandoz

https://pharmaphorum.com/news/swiss-socialists-say-government-should-buy-sandoz/

Podcast/ Video/ Views and analysis

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast

Dominic Tyer biosimilars, Regulatory affairs, Sandoz 0 Comment

In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast

https://pharmaphorum.com/video/sandozs-pierre-bourdage-biosimilars/

News/ News/ Sales and Marketing

Novartis looking into future of its Sandoz’ generics business

Phil Taylor Financial, generics, M&A, Novartis, Sandoz 0 Comment

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options –

Novartis looking into future of its Sandoz’ generics business

https://pharmaphorum.com/news/novartis-looking-into-future-of-its-sandoz-generics-business/

Podcast/ R&D/ Views & Analysis/ Views and analysis

Richard Francis on his Purespring plans: the pharmaphorum podcast

Dominic Tyer gene therapy, podcast, Purespring Therapeutics, Richard Francis, Sandoz 0 Comment

In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took

Richard Francis on his Purespring plans: the pharmaphorum podcast

https://pharmaphorum.com/r-d/richard-francis-purespring-gene-therapy-podcast/

News/ News/ Sales and Marketing

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs

Phil Taylor antibiotic, antimicrobial resistance, GlaxoSmithKline, Novartis, Sandoz 0 Comment

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs

https://pharmaphorum.com/news/novartis-antibiotic-retreat-doesnt-stop-sandoz-buying-gsk-drugs/

Trending

Sandoz

Login